BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 26, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 2002

View Archived Issues

Promising early clinical results for dexosome vaccine in melanoma

Read More

Clinical data on the proteasome inhibitor PS-341 in multiple myeloma updated

Read More

Influence of renal dysfunction on safety profile of pemetrexed

Read More

Pharmacokinetics of epothilone B assessed in patients with advanced cancer

Read More

Tadalafil reported safe and effective in broad-spectrum erectile dysfunction

Read More

No beneficial effects found for nutritional supplementation in fibromyalgia

Read More

Preliminary data suggest potential for pramipexole in fibromyalgia

Read More

Potential use of pregabalin in fibromyalgia

Read More

Novel mu-selective opioid ligand identified at Purdue Pharma

Read More

Dyax and Thios enter therapeutic antibody discovery and development collaboration

Read More

Chemokine CCR2 and/or CCR3 antagonists under study at Pfizer

Read More

Ferring and Johnson & Johnson to develop new generation of type 2 diabetes drugs

Read More

NeuroSearch claims modulators of monoamine receptors and transporters with broad applications

Read More

Prodrug-based antiinfectives objective of Ricerca and ProQuest collaboration

Read More

Novel HIV reverse transcriptase inhibitors in Medivir pipeline

Read More

Pharmacia researchers describe new CDK inhibitors for cancer and other indications

Read More

Progen receives clearance to begin PI-166 clinical trial

Read More

Servier and ConjuChem report novel albumin-binding metalloproteinase inhibitors

Read More

Serono and Ivax to develop and commercialize oral cladribine for MS

Read More

Novartis to sell Leucomax rights to Schering-Plough

Read More

Oryx to market Angiomax in Canada

Read More

Replagal E.U. labeling expanded to include treatment of females

Read More

Potential for OPC-14523 in bulimia nervosa and OCD

Read More

Novel mglu5 receptor antagonists as potential anxiolytic agents

Read More

Anxiolytic profile of PNU-57378E evaluated in rodent models

Read More

Novartis acquires rights to AGE breaker from Torrent

Read More

SuperGen to begin Orathecin NDA submission by year-end 2002

Read More

Biovail receives tentative FDA approval for Flash Dose zolpidem

Read More

Pravachol approved for use in pediatric patients

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing